Clinical Trials | August 18, 2022
Sanofi updates on amcenestrant clinical development program
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
The Supervisory Board has unanimously decided to propose Roy Jakobs as the next President and CEO of Royal Philips to its General Meeting of Shareholders.
The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Collaboration supports multiple discovery efforts, including vaccines
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Subscribe To Our Newsletter & Stay Updated
